Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Mol Ther
; 29(3): 908-919, 2021 03 03.
Article
en En
| MEDLINE
| ID: mdl-33388422
ABSTRACT
A growing amount of evidence suggests that ubiquitination and deubiquitination of programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) play crucial roles in the regulation of PD-1 and PD-L1 protein stabilization and dynamics. PD-1/PD-L1 is a major coinhibitory checkpoint pathway that modulates immune escape in cancer patients, and its engagement and inhibition has significantly reshaped the landscape of tumor clearance. The abnormal ubiquitination and deubiquitination of PD-1/PD-L1 influence PD-1/PD-L1-mediated immunosuppression. In this review, we describe the ubiquitination- and deubiquitination-mediated modulation of PD-1/PD-L1 signaling through a variety of E3 ligases and deubiquitinating enzymes (DUBs). Moreover, we briefly expound on the anticancer potential of some agents that target related E3 ligases, which further modulate the ubiquitination of PD-1/PD-L1 in cancers. Therefore, this review reveals the development of a highly promising therapeutic approach for cancer immunotherapy by targeting PD-1/PD-L1 ubiquitination.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ubiquitinación
/
Antígeno B7-H1
/
Receptor de Muerte Celular Programada 1
/
Inmunoterapia
/
Neoplasias
Límite:
Animals
/
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article